Method for constructing ortho-tetra-substituted N-hetero-biaryl N-oxide

By using direct C-H bond activation coupling reaction, the cumbersome pre-functionalization steps and poor selectivity of traditional synthesis methods are solved, and the efficient generation of tetrasubstituted N-heterocyclic aromatic N-oxides is achieved. This method is suitable as an intermediate and starting material for a variety of ligands and catalysts.

CN120987843APending Publication Date: 2025-11-21ZHEJIANG UNIV OF TECH
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202510867790.1
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2025-06-26
Publication Date
2025-11-21

AI Technical Summary

Technical Problem

Existing techniques require pre-functionalization when synthesizing ortho-tetrasubstituted heterodiaryl compounds, which is cumbersome, has low atom economy, is difficult to be compatible with sterically hindered aryl reagents, and has poor regioselectivity and a narrow substrate range.

Method used

A method is employed to directly perform a carbon-hydrogen bond activation coupling reaction between N-heterocyclic N-oxides and aryl reagents in the presence of palladium, silver salts, ligands, and a base to generate ortho-tetrasubstituted N-heteroaryl N-oxides.

Benefits of technology

It achieves efficient and simple tetrasubstituted arylation reactions to generate tetrasubstituted N-heterocyclic aromatic N-oxides. It has wide applicability, mild reaction conditions, and good selectivity, and is suitable for intermediates and starting materials of a variety of ligands and catalysts.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN120987843A_ABST
    Figure CN120987843A_ABST
Patent Text Reader

Abstract

The invention discloses a method for constructing ortho-tetra-substituted N-hetero-linked aromatic hydrocarbon N-oxide, which comprises the following steps: by taking isoquinoline N-oxide as shown in a formula (I) and iodo-aromatic hydrocarbon as shown in a formula (II) or a formula (III) as raw materials, adding palladium acetate, silver carbonate, a ligand, alkali and a solvent, and replacing air with nitrogen flow or directly operating and reacting in a glove box to obtain the ortho-tetra-substituted N-hetero-linked aromatic hydrocarbon N-oxide. The ortho-tetra-substituted N-hetero-linked aromatic hydrocarbon N-oxide as shown in a formula (IV) or a formula (V) is prepared through post-treatment of a reaction solution, and the reaction equation is as follows: in the formula, X is C or N, and substituent groups R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12, R13, R14 and R15 are independently selected from H, methyl, phenyl, chlorine, fluorine, nitro, methyl ester group, cyano, phenoxy phenyl, methoxyl, ethyoxyl, propoxy, benzyloxy or phenylacetylene respectively. The method is wide in substrate adaptability, mild in reaction condition, simple to operate and good in arylation selectivity.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This invention belongs to the field of chemical organic synthesis technology, specifically relating to a method for constructing ortho-tetrasubstituted N-heteroaryl N-oxides. Background Technology

[0002] Axially chiral biaromatic compounds, as the core structures of natural products, chiral ligands, and catalysts, play an irreplaceable role in asymmetric catalysis, drug synthesis, and materials science. Their unique axial chiral center and multi-donor atom coordination ability enable them to precisely control enantioselective transformation processes through the synergistic interaction of nitrogen, oxygen, phosphorus, and other atoms with the metal center. For example, heterocyclic aromatic systems based on the isoquinoline skeleton, such as QUINOL (N,O coordination) and QUINAP (P,N coordination), have demonstrated excellent stereocontrol capabilities in asymmetric reactions such as hydrogenation and allylation.

[0003] Ortho-tetrasubstituted heterodiaryl compounds are important structural units in medicinal chemistry and materials science, but their traditional synthetic methods (such as Suzuki coupling) require prefunctionalization of the substrate (e.g., borylation or halogenation), which are cumbersome, have low atom economy, and are difficult to integrate with sterically hindered aryl reagents (such as 2,6-disubstituted aryl bromides / iodides). Furthermore, existing methods often suffer from poor regioselectivity and a narrow substrate range. Therefore, developing an efficient synthetic strategy that requires no pre-activation and can be directly activated via the CH bond is of great value.

[0004] Traditional synthetic routes primarily rely on cross-coupling reactions of pre-functionalized coupling reagents. For example, when Malkov et al. synthesized QUINOX via Suzuki-Miyaura coupling, halogen or borate ester functional groups needed to be introduced beforehand, and enantiomers had to be separated by subsequent resolution steps, resulting in limited synthetic efficiency (Angew. Chem., Int. Ed. 2003, 42, 3674). Furthermore, existing methods generally suffer from drawbacks such as a narrow substrate scope and demanding reaction conditions, particularly lacking effective strategies for the synthesis of heteroaryl hydrocarbons containing complex substituents. Summary of the Invention

[0005] To address the aforementioned problems, the present invention aims to provide a method for constructing ortho-tetrasubstituted N-heteroaryl N-oxides, achieving regioselective coupling of N-heterocyclic N-oxides with aryl reagents in one step to synthesize ortho-tetrasubstituted heterodiaryl N-oxides. The N-heterocyclic N-oxide and iodoaryl compounds undergo direct arylation of the C-H bond at position 1 of the N-heterocyclic N-oxide in the presence of palladium, silver salt, ligands, and a base, thereby synthesizing tetrasubstituted N-heterocyclic N-oxide biaryl compounds.

[0006] The specific technical solution is as follows:

[0007] A method for constructing ortho-tetrasubstituted N-heteroaromatic N-oxides includes the following steps: using isoquinoline N-oxides of formula (I) and iodoaromatics of formula (II) or (III) as raw materials, palladium acetate, silver carbonate, ligands, bases, and solvents are added. The reaction is carried out by replacing air with nitrogen or directly in a glove box. The reaction solution is then post-treated to obtain ortho-tetrasubstituted N-heteroaromatic N-oxides as shown in formula (IV) or (V). The reaction equation is as follows:

[0008]

[0009] In the formula, X is C or N, substituent R1 is H or methyl, substituent R2 is H, nitro or phenylethynyl, substituent R3 is H, methyl or chlorine, substituent R4 is H or phenoxyphenyl, and substituents R5 and R... 10 The substituent R6 is H or cyano, and the substituent R7 and R8 are H or phenyl. The substituent R9 is H or methyl ester. 11 H or methoxy group, substituent R 12 It is methoxy, chlorine or fluorine, and the substituent R 13 R 14 and R 15 It is a methoxy group, and the substituent R is present. 16 It is methyl or methoxy.

[0010] Further, the ligand is one of the following: 1,2-bis(diphenylphosphine)ethane, 2-dicyclohexylphosphine-2',6'-bis(N,N-dimethylamino)-1,1'-biphenyl, 2-biscyclohexylphosphine-2',6'-dimethoxy-1,1'-biphenyl, 2-biscyclohexylphosphine-2',6'-diisopropoxybiphenyl, 7,7'-bis(diphenylphosphine)-2,2',3,3'-tetrahydro-1,1'-spirodiinne, bis(2-diphenylphosphine) ether; the base is one of the following: sodium carbonate, potassium carbonate, potassium phosphate, sodium bicarbonate, potassium bicarbonate, 1,8-diazabicycloundec-7-ene, triethylamine, diisopropylethylamine; the solvent is one of the following: water, dioxane, toluene, tetrahydrofuran, N,N-dimethylformamide.

[0011] Furthermore, the solvent volume is 1–10 mL / mmol, calculated as the amount of iodoaromatic hydrocarbon shown in formula (II) or (III); the molar ratio of palladium acetate to iodoaromatic hydrocarbon shown in formula (II) or (III) is 1–10 mol%; the molar ratio of ligand to iodoaromatic hydrocarbon shown in formula (II) or (III) is 1.2–12 mol%; the molar ratio of silver carbonate to iodoaromatic hydrocarbon shown in formula (II) or (III) is 1–3:1; the molar ratio of base to iodoaromatic hydrocarbon shown in formula (II) or (III) is 1–3:1; and the molar ratio of N-heterocyclic N-oxide of formula (I) to iodoaromatic hydrocarbon shown in formula (II) or (III) is 0.5–3:1.

[0012] Furthermore, the reaction temperature is 50–140℃, and the reaction time is 12–48 h.

[0013] Furthermore, the molar ratio of palladium acetate to the iodoaromatic hydrocarbon represented by formula (II) or (III) is 1–5 mol%.

[0014] Furthermore, the molar ratio of the ligand to the iodoaryl hydrocarbon represented by formula (II) or (III) is 1.2–6 mol%.

[0015] Furthermore, the molar ratio of silver carbonate to the iodoaromatic hydrocarbons shown in formula (II) or formula (III) is 1 to 1.5:1.

[0016] Furthermore, the molar ratio of N-heterocyclic N-oxides of formula (I) to iodoaromatic hydrocarbons of formula (II) or (III) is 1.5 to 2:1.

[0017] Furthermore, the molar ratio of the base to the iodoaromatic hydrocarbon represented by formula (II) or formula (III) is 2 to 3:1.

[0018] Furthermore, the post-processing method for the reaction solution is as follows: after the reaction is completed, the reaction solution is purified and separated by column chromatography.

[0019] The beneficial effects of this invention are as follows:

[0020] 1) Compared with the traditional suzuki synthesis method, the present invention does not require the pre-installation of borate ester functional groups. It directly performs CH arylation in one step, which efficiently and rapidly generates tetrasubstituted arylation reaction with high yield and high functional group tolerance to produce tetrasubstituted N-heterocyclic aromatic N-oxides.

[0021] 2) The tetrasubstituted N-heterocyclic aromatic N-oxides synthesized in this invention have broad substrate adaptability, mild reaction conditions, simple operation, and good arylation selectivity. The obtained tetrasubstituted N-heterocyclic aromatic N-oxides are important intermediates and starting materials for many ligands and catalysts, and have broad application prospects. Therefore, this invention has high practical value. Detailed Implementation

[0022] The present invention will be further described below with reference to embodiments, but the scope of protection of the present invention is not limited thereto.

[0023] Example 1: Synthesis of 3a

[0024]

[0025] In a 25 mL Schlenk reactor, magnetic electrodes were added, followed by the sequential addition of isoquinoline N-oxide (Formula I-1, 87.0 mg, 0.6 mmol), 1-iodo-2-methoxynaphthalene (Formula II-1, 113.6 mg, 0.4 mmol, 1.0 equiv.), palladium acetate (4.48 mg, 5 mol%), DPEphos (12.9 mg, 6 mol%), silver carbonate (66.0 mg, 0.4 mmol, 1.0 equiv.), and potassium phosphate (254.4 mg, ... 1.2 mmol (3.0 equiv.), 4 mL toluene, stirred at 60 °C for 48 h; after the reaction, the reaction solution was purified by column chromatography, the toluene was removed from the reaction solution under reduced pressure, 5 mL of water was added to the residue, and then extracted with dichloromethane and methanol (10:1) (5 mL × 3), the solvent was removed under reduced pressure, and the product was separated by column chromatography (eluent ratio: dichloromethane to methanol volume ratio of 20:1), the eluent containing the product was collected, and the solvent was removed from the eluent to obtain 98.7 mg of 3a (formula IV-1), with a yield of 82%.

[0026] 1 H NMR (400MHz, CDCl3) δ8.39(d,J=7.2Hz,1H),8.07(d,J=9.1Hz,1H),7.89(dd,J=7.8,1.6Hz,1H),7.87-7.82(m,1H),7.75(d,J=7.2Hz,1 H),7.52(ddd,J=8.1,7.0,1.2Hz,1H),7.47(d,J=9.1Hz,1H),7.41-7.29(m,4H),7.16(d,J=8.4Hz,1H),7.11-7.04(m,1H),3.84(s,3H).

[0027] 13C NMR (101MHz, CDCl3) δ155.55,143.44,137.64,132.59,131.85,130.35,129.20,129.18,128.82, 128.45,128.27,127.53,126.94,125.46,124.05,123.87,123.64,113.63,113.56,56.65,21.19.

[0028] HRMS(ESI):calcd for C 20 H 16 NO2 + [M+H] + 302.1176, found 302.1176.

[0029] Example 2: Synthesis of 3b

[0030]

[0031] The method was the same as in Example 1, except that 1-iodo-2-ethoxynaphthalene (Formula II-2, 0.4 mmol, 1.0 equiv.) was different, yielding 99 mg of 3b (Formula IV-2) with a yield of 78%.

[0032] 1 H NMR (400MHz, CDCl3) δ8.41(d,J=6.9Hz,1H),8.06(d,J=9.1Hz,1H),7.94-7.83(m,2H),7.78(d,J=6.9Hz,1H),7.55(t,J=7.5Hz,1H),7.4 5(d,J=9.1Hz,1H),7.43-7.29(m,3H),7.19(d,J=8.4Hz,1H),7.08(d,J=8.1Hz,1H),4.15(qt,J=6.9,3.6Hz,2H),1.12(t,J=6.9Hz,3H).

[0033] 13 C NMR (101MHz, CDCl3) δ154.97,143.68,137.58,132.60,131.74,130.35,129.26,129.06,128.77, 128.42,128.24,127.46,126.84,125.61,124.08,123.95,123.54,115.10,114.33,65.23,14.93.

[0034] HRMS(ESI):calcd for C 21 H18 NO2 + [M+H] + 316.1332, found 316.1333.

[0035] Example 3: Synthesis of 3c

[0036]

[0037] The method was the same as in Example 1, except that 1-iodo-2-isopropyloxynaphthalene (Formula II-3, 0.4 mmol, 1.0 equiv.) was different, yielding 108 mg of 3c (Formula IV-3) with a yield of 82%.

[0038] 1 H NMR (400MHz, CDCl3) δ8.39(d,J=7.2Hz,1H),8.04(d,J=9.0Hz,1H),7.93-7.82(m,2H),7.76(d,J=7.2Hz,1H),7.54(ddd,J=8.2,6.9,1.2Hz,1H) ,7.47-7.29(m,4H),7.19(dd,J=8.5,1.1Hz,1H),7.10(dd,J=8.4,1.4Hz,1H),4.65-4.52(m,1H),1.12(d,J=6.1Hz,3H),1.08(d,J=6.0Hz,3H).

[0039] 13 C NMR (101MHz, CDCl3) δ154.36,143.71,137.58,132.71,131.53,130.35,129.39,128.96,128.59,128 .39,128.11,127.39,126.74,125.69,124.20,124.04,123.47,117.03,115.83,72.53,22.38,22.35.

[0040] HRMS(ESI):calcd for C 22 H 20 NO2 + [M+H] + 330.1489, found 330.1490.

[0041] Example 4: Synthesis of 3D

[0042]

[0043] The method was the same as in Example 1, except that 1-iodo-2-benzyloxynaphthalene (Formula II-4, 0.4 mmol, 1.0 equiv.) was different, yielding 127 mg of 3d (Formula IV-4) with a yield of 84%.

[0044] 1 H NMR (400MHz, CDCl3) δ8.41(d,J=7.1Hz,1H),8.03(d,J=9.0Hz,1H),7.93-7.83(m,2H),7.77(d,J=7.1Hz,1H),7.54(ddd,J=8.2,6.9,1.2Hz,1H) ,7.46(d,J=9.0Hz,1H),7.36(dddd,J=16.4,8.3,6.8,1.4Hz,3H),7.24-7.17(m,4H),7.13(ddd,J=12.4,7.0,1.9Hz,3H),5.19(d,J=1.9Hz,2H).

[0045] 13 C NMR (101MHz, CDCl3) δ154.74,143.34,137.65,137.00,132.67,131.70,130.42,129.45,129.13,128.68,128. 45,128.31,128.18,127.61,127.53,126.89,126.87,125.56,124.29,124.07,123.63,115.39,114.81,71.21.

[0046] HRMS(ESI):calcd for C 26 H 20 NO2 + [M+H] + 378.1489, found 378.1490.

[0047] Example 5: Synthesis of 3e

[0048]

[0049] The method was the same as in Example 1, except that 1-iodo-2-(methoxymethyl)naphthalene (Formula II-5, 0.4 mmol, 1.0 equiv.) was different, yielding 113 mg of 3e (Formula IV-5) in 85% yield.

[0050] 1H NMR (400MHz, CDCl3) δ8.40(d,J=7.1Hz,1H),8.06(d,J=9.1Hz,1H),7.94-7.85(m,2H),7. 79(d,J=7.2Hz,1H),7.63(d,J=9.1Hz,1H),7.55(ddd,J=8.2,6.9,1.1Hz,1H),7.40(dddd, J=8.1,6.8,3.9,1.3Hz,2H),7.33(ddd,J=8.3,6.8,1.4Hz,1H),7.19(dd,J=8.5,1.1Hz,1H ),7.09(dd,J=8.4,1.2Hz,1H),5.26(d,J=6.9Hz,1H),5.06(d,J=7.0Hz,1H),3.26(s,3H).

[0051] 13 C NMR (101MHz, CDCl3) δ153.33,143.29,137.60,132.47,131.72,130.34,129.85,129.18,128.75,128.45,12 8.31,127.48,126.90,125.46,124.53,124.05,123.69,116.45,115.12,94.95,77.42,77.10,76.78,56.07.

[0052] HRMS(ESI):calcd for C 21 H 18 NO3 + [M+H] + 332.1281, found 332.1280.

[0053] Example 6: Synthesis of 3f

[0054]

[0055] The method was the same as in Example 1, except that methyl 6-(benzyloxy)-5-iodo-1-naphthyl ester (Formula II-6, 0.4 mmol, 1.0 equiv.) was different, yielding 120 mg of 3f (Formula IV-6) in a yield of 69%.

[0056] 1H NMR (400MHz, CDCl3) δ9.12(d,J=9.6Hz,1H),8.04(dd,J=6.8,1.6Hz,1H),7.83(d,J=8.1Hz,1H),7.75(d,J=7.2 Hz,1H),7.57-7.51(m,2H),7.39-7.29(m,3H),7.20-7.14(m,3H),7.13-7.04(m,3H),5.17(s,2H),3.99(s,3H).

[0057] 13 C NMR (101MHz, CDCl3) δ167.90,154.61,142.85,137.51,136.62,133.19,130.31,129.69,129.17,129.08,128.60,128.38,128.25 ,128.20,127.61,127.59,127.05,126.85,126.76,126.20,125.25,123.74,116.56,114.85,77.35,77.03,76.71,70.83,52.18.

[0058] HRMS(ESI):calcd for C 28 H 22 NO4 + [M+H] + 436.1543, found 436.1541.

[0059] Example 7: Synthesis of 3g

[0060]

[0061] The method was the same as in Example 1, except that 6-(benzyloxy)-5-iodo-2-naphthoonitrile (Formula II-7, 0.4 mmol, 1.0 equiv.) was different, yielding 3 g (Formula IV-7) 114 mg, with a yield of 71%.

[0062] 1 H NMR (400MHz, CDCl3) δ8.37(d,J=7.2Hz,1H),8.24(d,J=1.7Hz,1H),8.04(d,J=9.2Hz,1H),7.87(d,J=8.2Hz,1H),7.79 (d,J=7.2Hz,1H),7.60-7.52(m,2H),7.43(dt,J=9.3,1.8Hz,2H),7.22-7.14(m,4H),7.12-7.05(m,3H),5.19(s,2H).

[0063] 13 C NMR (101MHz, CDCl3) δ157.04,141.82,137.53,136.13,134.62,134.30,132.30,130.08,129.40,128.64,128.41,1 28.38,127.97,127.88,127.84,127.07,126.72,125.30,124.91,124.04,119.25,116.50,114.91,107.43,70.91.

[0064] HRMS(ESI):calcd for C 27 H 19 N2O2 + [M+H] + 403.1441, found 403.1439.

[0065] Example 8: Synthesis over 3 hours

[0066]

[0067] The method was the same as in Example 1, except that 1-iodo-2,7-dimethoxynaphthalene (Formula II-8, 0.4 mmol, 1.0 equiv.) was different, yielding 78 mg of 3h (Formula IV-8), with a yield of 59%.

[0068] 1 H NMR (400MHz, CDCl3) δ8.37(d,J=7.2Hz,1H),7.95(d,J=9.0Hz,1H),7.82(dt,J =8.2,0.9Hz,1H),7.74(dd,J=13.1,8.1Hz,2H),7.50(ddd,J=8.2,6.9,1.2Hz,1 H),7.37(ddd,J=8.3,6.9,1.2Hz,1H),7.26(s,1H),7.16(dd,J=8.4,1.0Hz,1H) ,7.00(dd,J=8.9,2.5Hz,1H),6.27(d,J=2.5Hz,1H),3.79(s,3H),3.54(s,3H).

[0069] 13C NMR (101MHz, CDCl3) δ158.83,156.06,143.53,137.45,133.91,131.38,130.04,129.93,129.05,128.68,128. 16,126.79,125.38,124.58,123.48,116.33,116.30,112.38,110.62,110.60,102.39,102.35,56.35,54.91.

[0070] HRMS(ESI):calcd for C 21 H 18 NO3 + [M+H] + 332.1281, found 332.1283.

[0071] Example 9: Synthesis of 3i

[0072]

[0073] The method was the same as in Example 1, except that 1-chloro-2-iodo-3-methylbenzene (Formula III 1, 0.4 mmol, 1.0 equiv.) was different, yielding 84 mg of 3i (Formula V-1) with a yield of 78%.

[0074] 1 H NMR (400MHz, CDCl3) δ8.30(d,J=7.1Hz,1H),7.84(d,J=8.0Hz,1H),7.73(d,J=7.2Hz,1H),7.55(ddd,J=1 7.0,8.4,7.1Hz,2H),7.44-7.37(m,2H),7.30(dd,J=7.3,1.6Hz,1H),7.18(d,J=8.3Hz,1H),2.05(s,3H).

[0075] 13 C NMR (101MHz, CDCl3) δ144.00,139.97,139.92,137.21,134.03,130.53,129.91,1 29.59,128.97,128.71,128.57,128.40,127.20,127.05,124.14,123.86,19.62.

[0076] HRMS(ESI):calcd for C 16 H 13 ClNO + [M+H] +270.0680, found 270.0683.

[0077] Example 10: Synthesis of 3j

[0078]

[0079] The method was the same as in Example 1, except that 1-fluoro-2-iodo-3-methylbenzene (Formula III-2, 0.4 mmol, 1.0 equiv.) was different, yielding 89 mg of 3j (Formula V-2), with a yield of 88%.

[0080] 1 H NMR (400MHz, CDCl3) δ8.39(d,J=7.2Hz,1H),7.95-7.89(m,1H),7.81(d,J=7.2Hz,1H),7.63(dddd,J=20.7,8.3,7.0,1. 3Hz,2H),7.52(td,J=8.0,5.8Hz,1H),7.36(d,J=8.0Hz,1H),7.29(d,J=7.6Hz,1H),7.18(t,J=8.7Hz,1H),2.19(s,3H).

[0081] 13 C NMR (101MHz, CDCl3) δ160.25 (d, J = 247.3Hz), 141.32, 140.49 (d, J = 2.5Hz), 137.41, 131.12 (d, J = 8.9Hz), 129.54, 128.53 ,128.38,127.03,125.98(d,J=3.0Hz),124.54,123.92,118.62(d,J=16.0Hz),113.27(d,J=21.4Hz),19.19(d,J=2.5Hz).

[0082] 19 F NMR (376MHz, CDCl3) δ-113.42.

[0083] HRMS(ESI):calcd for C 16 H 13 FNO + [M+H] + 254.0976, found 254.0973.

[0084] Example 11: Synthesis of 3k

[0085]

[0086] The method was the same as in Example 1, except that 3-methylisoquinoline-N-oxide (Formula I-2, 0.6 mmol, 1.5 equiv.) was different, yielding 86 mg of 3k (Formula IV-9) in 68% yield.

[0087] 1 H NMR (400MHz, CDCl3) δ8.07(d,J=9.1Hz,1H),7.93-7.87(m,1H),7.80(d,J=9.1Hz,2H),7.54-7.45( m,2H),7.38-7.29(m,3H),7.12(d,J=8.5Hz,1H),7.02(d,J=8.3Hz,1H),3.83(s,3H),2.75(s,3H).

[0088] 13 C NMR (101MHz, CDCl3) δ155.30,146.34,143.23,132.65,131.36,129.18,129.12,128.59, 128.29,127.83,127.44,126.01,125.09,123.83,122.53,114.42,113.31,56.48,18.23.

[0089] HRMS(ESI):calcd for C 21 H 18 NO2 + [M+H] + 316.1332, found 316.1335.

[0090] Example 12: Synthesis of 3l

[0091]

[0092] The method was the same as in Example 1, except that 5-(phenylethynyl)isoquinoline-N-oxide (Formula I-3, 0.6 mmol, 1.5 equiv.) was different, yielding 3l (Formula IV-10) 129 mg, with a yield of 80%.

[0093] 1H NMR (400MHz, CDCl3) δ8.35(d,J=7.3Hz,1H),8.22(d,J=6.9Hz,1H),7.94(d,J=9.1Hz,1H),7.80-7.71(m,1H),7.62(dd,J=7.3,1. 1Hz,1H),7.57-7.52(m,2H),7.36-7.27(m,4H),7.26-7.17(m,3H),7.00(dt,J=8.5,1.0Hz,1H),6.96-6.92(m,1H),3.70(s,3H).

[0094] 13 C NMR (101MHz, CDCl3) δ155.39,143.39,138.06,132.38,131.85,131.76,131.63,130.26,128.99,128.90,128.82,128.68,128.4 5,128.33,127.48,125.54,123.94,123.58,122.37,121.97,120.82,113.30,113.16,95.70,85.47,56.44.HRMS(ESI):calcdfor C 28 H 20 NO2 + [M+H] + 402.1489, found 402.1492.

[0095] Example 13: Synthesis of 3m

[0096]

[0097] The method was the same as in Example 1, except that 5-nitroisoquinoline-N-oxide (Formula I-4, 0.6 mmol, 1.5 equiv.) was different, yielding 3m (Formula IV-11) 114 mg, with a yield of 82%.

[0098] 1 H NMR (400MHz, CDCl3) δ8.64(d,J=7.7Hz,1H),8.53(d,J=7.8Hz,1H),8.29(t,J=4.4Hz,1H),8.10(d,J=9.1H z,1H),7.91(dd,J=7.4,2.0Hz,1H),7.50-7.45(m,3H),7.41-7.32(m,2H),7.05-6.99(m,1H),3.85(s,3H).

[0099] 13C NMR (101MHz, CDCl3) δ155.49,145.49,143.43,140.34,132.38,132.23,131.71,131.69,129. 02,128.52,127.94,127.82,125.46,124.17,123.28,120.82,119.05,113.15,112.32,56.43.

[0100] HRMS(ESI):calcd for C 20 H 15 N2O4 + [M+H] + 347.1026, found 347.1025.

[0101] Example 14: Synthesis of 3n

[0102]

[0103] The method was the same as in Example 1, except that 6-methylisoquinoline-N-oxide (Formula I-5, 0.6 mmol, 1.5 equiv.) was different, yielding 92 mg of 3n (Formula IV-12) with a yield of 73%.

[0104] 1 H NMR (400MHz, CD3OD) δ8.36(d,J=7.1Hz,1H),8.20(d,J=9.2Hz,1H),8.04(d,J=7.2Hz,1H),7.98(dd,J=7.7,1.3Hz,1H),7.88(s,1H),7.63(d,J= 9.2Hz,1H),7.43-7.36(m,2H),7.33(ddd,J=8.2,6.8,1.4Hz,1H),7.10(d,J=8.7Hz,1H),6.91(dt,J=8.3,1.0Hz,1H),3.85(s,3H),2.55(s,3H).

[0105] 13 C NMR(101MHz,CD3OD)δ155.59,148.27,140.90,135.81,132.36,131.93,131.69,130.80,129.08, 128.18,128.04,127.23,126.03,125.59,123.96,123.72,123.03,112.99,112.33,55.40,20.29.

[0106] HRMS(ESI):calcd for C21 H 18 NO2 + [M+H] + 316.1332, found 316.1330.

[0107] Example 15: Synthesis of 3o

[0108]

[0109] The method was the same as in Example 1, except that 6-chloroisoquinoline-N-oxide (Formula I-6, 0.6 mmol, 1.5 equiv.) was different, yielding 112 mg of 3o (Formula IV-13), with a yield of 83%.

[0110] 1 H NMR (400MHz, CDCl3) δ8.38(d,J=7.2Hz,1H),8.08(d,J=9.5Hz,1H),7.93-7.87(m,1H),7.84(d,J=2.1Hz,1H),7.68(d,J=7. 2Hz,1H),7.46(d,J=9.1Hz,1H),7.34(ddd,J=16.9,8.4,1.7Hz,3H),7.10(d,J=9.0Hz,1H),7.07-7.00(m,1H),3.85(s,3H).

[0111] 13 C NMR (101MHz, CDCl3) δ155.44,143.41,138.64,134.31,132.34,132.03,129.98,129.29,129.06, 128.70,128.43,127.61,127.05,125.78,124.06,123.55,122.55,113.30,112.87,56.56,56.51.

[0112] HRMS(ESI):calcd for C 20 H 15 ClNO2 + [M+H] + 336.0786, found 336.0785.

[0113] Example 16: Synthesis of 3p

[0114]

[0115] The method was the same as in Example 1, except that 7-(4-phenoxyphenyl)isoquinoline-N-oxide (Formula I-7, 0.6 mmol, 1.5 equiv.) was different, yielding 137 mg of 3p (Formula IV-14) in 73% yield.

[0116] 1 H NMR(400MHz, CDCl3)δ8.37(d,J=7.4Hz,1H),8.10(d,J=9.1Hz,1H),7.95-7.87(m,2H),7 .53-7.48(m,4H),7.46-7.41(m,3H),7.40-7.33(m,2H),7.22-7.14(m,7H),3.89(s,3H).

[0117] 13 C NMR (101MHz, CDCl3) δ157.69,156.66,156.63,155.59,143.36,139.35,137.55,133.45,132.65,131.89,131.29,130.93,130.01,1 29.26,129.09,128.91,128.49,127.58,127.48,127.14,124.84,124.10,123.93,121.81,119.57,118.59,113.91,113.62,56.74.

[0118] HRMS(ESI):calcd for C 32 H 24 NO3 + [M+H] + 470.1751, found 470.1753.

[0119] Example 17: Synthesis of 3q

[0120]

[0121] The method was the same as in Example 1, except that 8-cyanoisoquinoline-N-oxide (Formula I-8, 0.6 mmol, 1.5 equiv.) was different, yielding 3q (Formula IV-15) 69 mg, with a yield of 52%.

[0122] 1H NMR (400MHz, CDCl3) δ8.46(d,J=7.2Hz,1H),8.19(d,J=9.2Hz,1H),8.07(dd,J=8.2,1.3Hz,1H),7.96-7.86(m,2H),7.83 (d,J=7.2Hz,1H),7.57(dd,J=8.2,7.3Hz,1H),7.46(d,J=9.1Hz,1H),7.40-7.31(m,2H),7.02-6.96(m,1H),3.89(s,3H).

[0123] 13 C NMR (101MHz, CDCl3) δ156.83,142.72,139.02,138.96,133.40,133.20,132.28,129.31,129. 01,128.94,128.89,127.74,126.98,124.01,122.50,116.06,112.93,112.30,108.06,56.37.

[0124] HRMS(ESI):calcd for C 21 H 15 N2O2 + [M+H] + 327.1128, found 327.1126.

[0125] Example 18: Synthesis of 3r

[0126]

[0127] A magnetic oscillator was added to a 25 mL Schlenk reactor, followed by the sequential addition of phthalazine-N-oxide (Formula I-9, 0.6 mmol), 1-iodo-2-methoxynaphthalene (Formula II-1, 113.6 mg, 0.4 mmol, 1.0 equiv.), palladium acetate (4.48 mg, 5 mol%), DPEphos (12.9 mg, 6 mol%), silver carbonate (66.0 mg, 0.4 mmol, 1.0 equiv.), and potassium phosphate (254.4 mg, 1.2 mmol, ... 3.0 equiv.), 4 mL toluene, stirred at 60 °C for 48 h; after the reaction, the reaction solution was purified by column chromatography, the toluene was removed from the reaction solution under reduced pressure, 5 mL of water was added to the residue, and then extracted with dichloromethane and methanol (10:1) (5 mL × 3), the solvent was removed under reduced pressure, and the product was separated by column chromatography (eluent ratio: dichloromethane to methanol volume ratio of 20:1), the eluent containing the product was collected, and the solvent was removed from the eluent to obtain 91 mg of 3r (formula IV-16), with a yield of 75%.1 HNMR (400MHz, CDCl3) δ9.19(s,1H),8.06(d,J=9.0Hz,1H),7.98(d,J=7.2Hz,1H),7.88(dd,J=7.3,1.9H z,1H),7.60(p,J=7.3Hz,2H),7.45(d,J=9.0Hz,1H),7.40-7.30(m,2H),7.17-7.06(m,2H),3.84(s,3H).

[0128] 13 C NMR (101MHz, CDCl3) δ155.64,152.27,133.79,133.67,133.64,132.24,132.12,129.20,1 28.82,128.57,127.69,127.31,124.19,124.17,123.59,120.83,113.51,112.30,56.67.

[0129] HRMS(ESI):calcd for C 19 H 15 N2O2 + [M+H] + 303.1128, found 303.1130.

[0130] Example 19: Synthesis of 3s

[0131]

[0132] The method was the same as in Example 18, except that 1-iodo-2-ethyloxynaphthalene (Formula II-2, 0.4 mmol, 1.0 equiv.) was different, yielding 91 mg of 3s (Formula IV-17) with a yield of 72%.

[0133] 1 H NMR (400MHz, CDCl3) δ9.19 (d, J = 0.8Hz, 1H), 8.08-8.02 (m, 1H), 8.01-7.95 (m, 1H), 7.92-7.86 (m, 1H), 7.65-7.5 6(m,2H),7.43(d,J=9.1Hz,1H),7.39-7.30(m,2H),7.18-7.09(m,2H),4.23-4.09(m,2H),1.14(t,J=7.0Hz,3H). 13C NMR (101MHz, CDCl3) δ155.06,152.16,135.07,133.79,133.49,132.16,132.10,129.25,128. 71,128.54,127.60,127.22,124.29,124.18,123.68,120.73,114.87,112.94,65.20,14.90.

[0134] HRMS(ESI):calcd for C 20 H 17 N2O2 + [M+H] + 317.1285, found 317.1287.

[0135] Example 20: Synthesis of 3t

[0136]

[0137] The method was the same as in Example 18, except that 1-iodo-2-methoxy-4-phenylnaphthalene (Formula II-9, 0.4 mmol, 1.0 equiv.) was different, yielding 3t (Formula IV-18) 133 mg, with a yield of 88%.

[0138] 1 H NMR(400MHz, CDCl3)δ9.22(s,1H),8.04-7.96(m,1H),7.90(dd,J=7.9,1.8Hz,1H),7.69-7.59(m,4H),7.58-7.53(m, 2H),7.53-7.48(m,1H),7.40(s,1H),7.37-7.29(m,2H),7.25(dd,J=6.2,3.3Hz,1H),7.21-7.14(m,1H),3.86(s,3H).

[0139] 13 C NMR (101MHz, CDCl3) δ154.74,152.16,144.54,140.14,134.91,133.73,133.57,132.44,129.85,128.76,1 28.32,127.71,127.54,127.50,127.20,126.81,124.16,124.11,123.79,120.75,114.50,111.59,56.49.

[0140] HRMS(ESI):calcd for C 25 H 19 N2O2+ [M+H] + 379.1441, found 379.1440.

[0141] Example 21: Synthesis of 3u

[0142]

[0143] The method was the same as in Example 18, except that 1-iodo-2-methoxy-3-phenylnaphthalene (Formula II-10, 0.4 mmol, 1.0 equiv.) was different, yielding 105 mg of 3u (Formula IV-19) with a yield of 69%.

[0144] 1 H NMR (400MHz, CDCl3) δ9.26 (s, 1H), 8.08 (s, 1H), 8.06-8.00 (m, 1H), 7.96 (d, J = 8.2Hz, 1H), 7.76-7.71 (m, 2H), 7.70-7.6 6(m,2H),7.48(dtd,J=7.9,6.1,1.3Hz,3H),7.44-7.35(m,2H),7.33-7.27(m,1H),7.17(d,J=8.3Hz,1H),3.37(s,3H).

[0145] 13 C NMR (101MHz, CDCl3) δ154.80,152.44,137.81,135.08,134.86,133.95,133.66,132.85,131.18,131.09,1 29.15,129.08,128.64,128.44,127.60,127.46,127.24,125.71,124.12,123.78,120.76,119.06,61.07.

[0146] HRMS(ESI):calcd for C 25 H 19 N2O2 + [M+H] + 379.1441, found 379.1443.

[0147] Example 22: Synthesis of 3V

[0148]

[0149] A magnetic oscillator was added to a 25 mL Schlenk reactor, followed by the sequential addition of phthalazine-N-oxide (Formula I-9, 0.6 mmol), 1-iodo-2,3,4,5-tetramethoxy-6-methylbenzene (Formula III-3, 0.4 mmol, 1.0 equiv.), palladium acetate (4.48 mg, 5 mol%), DPEphos (12.9 mg, 6 mol%), silver carbonate (66.0 mg, 0.4 mmol, 1.0 equiv.), and potassium phosphate (254.4 mg, 1.2 mmol). 3.0 ol (equiv.), 4 mL toluene, stirred at 60 °C for 48 h; after the reaction, the reaction solution was purified by column chromatography, the toluene was removed from the reaction solution under reduced pressure, 5 mL of water was added to the residue, and then extracted with dichloromethane and methanol (10:1) (5 mL × 3), the solvent was removed under reduced pressure, and the product was separated by column chromatography (eluent ratio: dichloromethane to methanol volume ratio of 20:1), the eluent containing the product was collected, and the solvent was removed from the eluent to obtain 3r (formula V-3) 89 mg, yield 62%. 1 HNMR (400MHz, CDCl3) δ9.14 (s, 1H), 7.97 (d, J = 8.0Hz, 1H), 7.72 (t, J = 7.6Hz, 1H), 7.66 (t, J = 7.4 Hz,1H),7.26(d,J=8.3Hz,1H),4.05(s,3H),3.97(s,3H),3.89(s,3H),3.70(s,3H),1.91(s,3H).

[0150] 13 C NMR (101MHz, CDCl3) δ152.11,148.53,148.44,147.75,145.16,135.44,133.83,133.26 ,128.97,127.22,126.47,123.90,120.78,118.86,61.43,61.27,61.08,60.89,12.25.

[0151] HRMS(ESI):calcd for C 19 H 21 N2O5 + [M+H] + 357.1445, found 357.1443.

[0152] Example 23: Synthesis of 3w

[0153]

[0154] The method was the same as in Example 22, except that 2-iodo-3,5-dimethoxybenzaldehyde (Formula III-4, 0.4 mmol, 1.0 equiv.) was used to obtain 3w (Formula V-4) 78 mg, with a yield of 63%.

[0155] 1 H NMR (400MHz, CDCl3) δ9.64 (s, 1H), 9.15 (d, J = 0.8Hz, 1H), 8.02-7.95 (m, 1H), 7.74 -7.62(m,2H),7.25-7.20(m,2H),6.89(d,J=2.4Hz,1H),3.97(s,3H),3.73(s,3H).

[0156] 13 C NMR (101MHz, CDCl3) δ190.03,190.01,162.62,159.01,152.16,136.66,133.97,133.70,1 28.84,127.32,123.52,120.69,113.43,105.65,105.02,56.25,55.92.HRMS(ESI):calcd for C 17 H 15 N2O4 + [M+H] + 311.1026, found 311.1025.

[0157] Example 24: Synthesis of 3x

[0158]

[0159] The method was the same as in Example 22, except that 2-iodo-1,3-dimethoxybenzene (Formula III-5, 0.4 mmol, 1.0 equiv.) was different, yielding 3x (Formula V-5) 65 mg, with a yield of 57%.

[0160] 1 H NMR (400MHz, CDCl3) δ9.08 (s, 1H), 7.92 (dt, J = 7.9, 1.0Hz, 1H), 7.69-7.64 (m, 1H), 7.63-7.60 ( m,1H),7.49(t,J=8.4Hz,1H),7.31(dd,J=8.3,1.1Hz,1H),6.74(d,J=8.4Hz,2H),3.72(s,6H).

[0161] 13C NMR (101MHz, CDCl3) δ158.60,151.66,133.63,133.12,131.93,128.36,126.99,124.23,120.80,107.61,104.45,56.06.

[0162] HRMS(ESI):calcd for C 16 H 15 N2O3 + [M+H] + 283.1077, found 283.1074.

[0163] Example 25: Isotope Labeling Experiment

[0164]

[0165] Table 1. Isotope labeling results under different conditions

[0166]

[0167] (1) Silver carbonate-mediated N-oxide isotope labeling experiment

[0168] In a glove box, silver carbonate (1.0 equiv.), isoquinoline N-oxide (0.3 mmol), and methanol-d4 (CD3OD, 10.0 equivalents) were added sequentially to a 10 mL reaction tube that had been dried in an oven, using toluene (2.0 mL) as the solvent. The mixture was stirred at 60 °C for 12 hours. The combined organic phases were washed with brine (2 × 10 mL), dried over anhydrous sodium sulfate, and concentrated. The residue was purified by column chromatography (eluting with dichloromethane / methanol in a gradient elution of 50 / 1 to 20 / 1), and the N-oxide was finally recovered. The deuteration rate was analyzed by 1H NMR spectroscopy. 1 H NMR (400MHz, CDCl3) δ8.70(s,0.98H),8.08(dd,J=7.1,1.8Hz,0.98H),7.78-7.71(m,1H),7.68-7.63(m,1H),7.61(d,J=7.1Hz,1H),7.59-7.50(m,2H).

[0169] (2) Palladium acetate and ligand-mediated isoquinoline N-oxide isotope labeling experiment

[0170] In a glove box, palladium acetate (5 mol%), ligand (7 mol%), N-oxide (0.3 mmol), and methanol-d4 (CD3OD, 10.0 equivalent) were added sequentially to a 10 mL reaction tube that had been dried in an oven, using toluene (2.0 mL) as the solvent. The mixture was stirred at 120 °C for 5 hours. The combined organic phases were washed with brine (2 × 10 mL), dried over anhydrous sodium sulfate, and concentrated. The residue was purified by column chromatography (eluting with dichloromethane / methanol in a gradient elution of 50 / 1 to 20 / 1), ultimately recovering isoquinoline N-oxide, and the deuteration rate was analyzed by 1H NMR spectroscopy. 1 H NMR(400MHz,Chloroform-d)δ8.70(s,0.97H),8.08(dd,J=7.1,1.8Hz,0.97H), 7.78-7.71(m,1H),7.68-7.63(m,1H),7.61(d,J=7.1Hz,1H),7.59-7.50(m,2H).

[0171] (3) Silver carbonate and ligand-mediated N-oxide isotope labeling experiments

[0172] In a glove box, silver carbonate (1.0 equiv.), ligand (20 mol%), N-oxide (0.3 mmol), and methanol-d4 (CD3OD, 10.0 equivalent) were added sequentially to a 10 mL reaction tube that had been dried in an oven, with toluene (2.0 mL) as the solvent. The mixture was stirred at 60 °C for 12 hours. The combined organic phases were washed with brine (2 × 10 mL), dried over anhydrous sodium sulfate, and concentrated. The residue was purified by column chromatography (eluting with dichloromethane / methanol in a gradient elution of 50 / 1 to 20 / 1), and the N-oxide was finally recovered. The deuteration rate was analyzed by 1H NMR spectroscopy. 1 H NMR (400MHz, CDCl3) δ8.70 (s, 0.42H), 8.08 (dd, J = 7.1, 1.8Hz, 0.86H), 7.78-7.71 (m, 1H), 7.68-7.63 (m, 1H), 7.61 (d, J = 7.1Hz, 1H), 7.59-7.50 (m, 2H).

[0173] Example 26: Synthesis of oxidative addition intermediate Complex A

[0174]

[0175] In the glove box, Pd(P tBu3)2 (1.0 mmol) and DPEphos (1.0 mmol) were placed in a 20 mL Schlenk tube equipped with a stir bar, followed by the addition of toluene (4.0 mL). The tube was sealed and quickly removed from the glove box. After stirring at 60 °C for 1 hour, the solution gradually turned yellow-green. Then, it was cooled to room temperature, and 2.0 mL of toluene solvent containing 1-iodo-2-methoxynaphthalene (2.0 mmol) was added to the glove box. The solution was heated to 60 °C and the reaction was continued for 12 hours. Gradually, a yellow solid was observed to precipitate from the solvent. After the reaction was completed, the temperature was lowered to room temperature, filtered in air, and the product was washed with toluene at 0 °C to obtain a bright yellow powder, Complex A. 1 H NMR (500MHz, CDCl3) δ8.30(s,1H),8.13-8.03(m,2H),7.81-7.71(m,2H),7.49-7.28(m,10H),7.23(ddd,J=8.0,4.7,1.3Hz,1H),7.12(dd,J=17.1,8. 3Hz,2H),7.06-6.80(m,9H),6.74(t,J=8.5Hz,1H),6.58(s,2H),6.44(t,J =7.5Hz,1H),6.38(dd,J=8.2,4.3Hz,1H),6.35-6.26(m,2H),3.39(s,3H). 31 P NMR (162MHz, CDCl3) δ7.70 (d, J = 30.3Hz), 4.23 (d, J = 30.1Hz).

[0176] Example 27: Procedure for using ComplexA as a catalyst

[0177]

[0178] In a glove box, Complex A (5.0 mol%), 1-iodo-2-methoxynaphthalene (0.4 mmol, 1.0 equiv.), silver carbonate (1.0 equiv.), potassium phosphate (3.0 equiv.), and isoquinoline N-oxide (0.6 mmol, 1.5 equiv.) were placed in a 10 mL Schlenk tube equipped with a stir bar, followed by the addition of toluene (4.0 mL). The tube was sealed, quickly removed from the glove box, and stirred at room temperature for 10 minutes. The solution was then heated to 60 °C and the reaction was allowed to proceed for 48 to 60 hours. After the reaction was complete, the mixture was quenched with water (4 mL) and extracted with ethyl acetate and methanol (EA:MeOH = 10:1) (10 mL × 2). The combined organic phases were washed with water (5 mL) and dried over anhydrous sodium sulfate (Na₂SO₄). After removing the solvent under reduced pressure, the residue was purified by silica gel column chromatography using [(dichloromethane:methanol = 10:1-20:1) or (ethyl acetate:methanol = 1:0-10:1)] as the eluent to obtain 3a 96 mg in 80% yield. This experiment verified that intermediate A plays a catalytic role in the reaction.

[0179] Example 27: Possible bimetallic synergistic catalytic reaction mechanism

[0180]

[0181] Based on the above experimental results, a possible Pd-Ag co-catalytic reaction mechanism is proposed: 1) Pd(0) species I undergoes oxidative addition with 1-iodo-2-methoxynaphthalene to generate complex A, which is then rapidly converted into aryl-Pd carbonate intermediate C via anion exchange; 2) Ag species II selectively activates the C1-H bond of 1a to generate aryl-silver intermediate D; 3) The transmetallation of C and D forms aryl-palladium-aryl species E; 4) E undergoes reductive elimination to generate the target product 3a.

Claims

1. A method for constructing ortho-tetrasubstituted N-heteroaryl N-oxides, characterized in that, The process includes the following steps: using isoquinoline N-oxides as shown in formula (I) and iodoaromatic hydrocarbons as shown in formula (II) or (III) as raw materials, palladium acetate, silver carbonate, ligands, bases, and solvents are added. The reaction is carried out by replacing the air with a nitrogen stream or directly in a glove box. The reaction solution is then post-treated to obtain ortho-tetrasubstituted N-heteroaromatic N-oxides as shown in formula (IV) or (V). The reaction equation is as follows: In the formula, X is C or N, substituent R1 is H or methyl, substituent R2 is H, nitro or phenylethynyl, substituent R3 is H, methyl or chlorine, substituent R4 is H or phenoxyphenyl, and substituents R5 and R... 10 The substituent R6 is H or cyano, and the substituent R7 and R8 are H or phenyl. The substituent R9 is H or methyl ester. 11 H or methoxy group, substituent R 12 It is methoxy, chlorine or fluorine, and the substituent R 13 R 14 and R 15 It is a methoxy group, and the substituent R is present. 16 It is methyl or methoxy.

2. The method for constructing ortho-tetrasubstituted N-heteroaryl N-oxides as described in claim 1, characterized in that, The ligand is one of the following: 1,2-bis(diphenylphosphine)ethane, 2-dicyclohexylphosphine-2',6'-bis(N,N-dimethylamino)-1,1'-biphenyl, 2-biscyclohexylphosphine-2',6'-dimethoxy-1,1'-biphenyl, 2-biscyclohexylphosphine-2',6'-diisopropoxybiphenyl, 7,7'-bis(diphenylphosphine)-2,2',3,3'-tetrahydro-1,1'-spirodiinne, bis(2-diphenylphosphine) ether; the base is one of the following: sodium carbonate, potassium carbonate, potassium phosphate, sodium bicarbonate, potassium bicarbonate, 1,8-diazabicycloundec-7-ene, triethylamine, diisopropylethylamine; the solvent is one of the following: water, dioxane, toluene, tetrahydrofuran, N,N-dimethylformamide.

3. The method for constructing ortho-tetrasubstituted N-heteroaryl N-oxides as described in claim 1, characterized in that, The solvent volume is 1–10 mL / mmol, calculated as the amount of iodoaromatic hydrocarbon shown in formula (II) or (III); the molar ratio of palladium acetate to iodoaromatic hydrocarbon shown in formula (II) or (III) is 1–10 mol%; the molar ratio of ligand to iodoaromatic hydrocarbon shown in formula (II) or (III) is 1.2–12 mol%; the molar ratio of silver carbonate to iodoaromatic hydrocarbon shown in formula (II) or (III) is 1–3:1; the molar ratio of base to iodoaromatic hydrocarbon shown in formula (II) or (III) is 1–3:1; and the molar ratio of N-heterocyclic N-oxide of formula (I) to iodoaromatic hydrocarbon shown in formula (II) or (III) is 0.5–3:

1.

4. The method for constructing ortho-tetrasubstituted N-heteroaryl N-oxides as described in claim 1, characterized in that, The reaction temperature is 50–140℃, and the reaction time is 12–48 h.

5. The method for constructing ortho-tetrasubstituted N-heteroaryl N-oxides as described in claim 3, characterized in that, The molar ratio of palladium acetate to the iodoaromatic hydrocarbon represented by formula (II) or (III) is 1–5 mol%.

6. The method for constructing ortho-tetrasubstituted N-heteroaryl N-oxides as described in claim 3, characterized in that, The molar ratio of the ligand to the iodoaryl hydrocarbon represented by formula (II) or (III) is 1.2–6 mol%.

7. The method for constructing ortho-tetrasubstituted N-heteroaryl N-oxides as described in claim 3, characterized in that, The molar ratio of silver carbonate to the iodoaromatic hydrocarbons shown in formula (II) or formula (III) is 1 to 1.5:

1.

8. The method for constructing ortho-tetrasubstituted N-heteroaryl N-oxides as described in claim 3, characterized in that, The molar ratio of N-heterocyclic N-oxides of formula (I) to iodoaromatic hydrocarbons of formula (II) or (III) is 1.5 to 2:

1.

9. The method for constructing ortho-tetrasubstituted N-heteroaryl N-oxides as described in claim 3, characterized in that, The molar ratio of the base to the iodoaromatic hydrocarbon shown in formula (II) or formula (III) is 2 to 3:

1.

10. The method for constructing ortho-tetrasubstituted N-heteroaryl N-oxides as described in claim 3, characterized in that, The post-processing method for the reaction solution is as follows: After the reaction is completed, the reaction solution is purified and separated by column chromatography.